Fig. 6: SASP from progeroid ECs induces CGRP overexpression, which is attenuated by dexamethasone treatment.

A Transcription level analysis of CDKIs and SASP expression in endothelial cells isolated from 4-week-old Tg or WT mice (n = 3 biologically independent cells per group). B SASP inhibition using dexamethasone injection schematic. C Representative images of toluidine blue staining in 10-week-old WT and Tg mice that received either dexamethasone or vehicle. D Quantification of mast cell degranulation (D) (n = 3 each). E Representative images of Masson’s trichrome staining in 10-week-old WT and Tg mice that received either dexamethasone or vehicle. F Quantification of the dermoepidermal junction surface area (F) (n = 3 each). G Representative immunoblotting for CGRP, p-NFκB, and P16 expression of whole skin lysate from 10-week-old WT or Tg mice, which received either dexamethasone or vehicle. H Densitometry quantification for immunoblotting in (H) (n = 3 each). I Transcription analysis of CDK inhibitors and SASP factors expression in the dermis and epidermis of either WT or Tg 10-week-old mice which received dexamethasone or vehicle (n = 3 each) Two-way ANOVA with Tukey’s post hoc test was used to analyze the differences between three or more groups. #P  <  0.0001; ***P  <  0.001; **P  <  0.01; *P  <  0.05. Not statistically significant (P  >  0.05).